Clinical trials: Lymphatic System Neoplasm
Diffuse Large B-Cell Lymphoma
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
This study is being done to evaluate if ME-401 can improve the treatment of patients with diffuse large b-celllymphoma (DLBCL). Many patients with DLBCL that are treated with the standard of care (R-CHOP) are cured.
- Trial name
- NCT04517435
- Testing
- ME-401, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Deepa Jagadeesh
Recurrent Adult Acute Lymphoblastic Leukemia
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
This phase II trial is studying how well giving combination chemotherapy together with alemtuzumab works in treating patients with relapsed or refractory acute lymphoblastic leukemia.
- Trial name
- NCT00262925
- Testing
- alemtuzumab, asparaginase, methotrexate
- Where
- 58 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
RATIONALE: Monoclonal antibodies, such as epratuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00945815
- Testing
- epratuzumab, clofarabine, cytarabine
- Where
- 81 sites in United States
- Volunteers
- 35 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00703664
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Mycosis Fungoides
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
This study will evaluate the efficacy, tolerability and safety of the topical application of mechlorethamine (MCH) formulations in patients with stage I or IIA mycosis fungoides (MF).
- Trial name
- NCT00168064
- Testing
- mechlorethamine-MCH (nitrogen mustard)
- Where
- 12 sites in United States
- Volunteers
- 260 people
- Sponsor
- Yaupon Therapeutics
B-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
This study evaluates the value of bortezomib in combination with specified chemotherapies for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL), Recurrent Adult Acute Lymphoblastic Leukemia (ALL), T-cell Adult Acute Lymphoblastic Leukemia (ALL)
- Trial name
- NCT01769209
- Testing
- Bortezomib, Doxorubicin hydrochloride (HCl), PEG-Asparaginase
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Burkitt Lymphoma, Retinoblastoma
Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment
Digital case management systems have the potential to increase compliance with protocol-driven treatment, reduce treatment abandonment and ultimately help to close the discrepancy in pediatric cancer outcomes between Low and…
- Conditions
- Burkitt Lymphoma, Retinoblastoma, Diffuse Large B-cell Lymphoma
- Trial name
- NCT03677128
- Testing
- mNavigator
- Where
- Tanzania
- Volunteers
- 75 people
- Sponsor
- Duke University
Leukemia, Hairy Cell
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Background: Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells.
- Trial name
- NCT01829711
- Testing
- Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox
- Where
- 34 sites in United States, Belgium and 12 more
- Volunteers
- 80 people
- Sponsor
- MedImmune LLC
Plasma Cell Myeloma
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant.
- Trial name
- NCT02880228
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Acute Leukaemia, Chronic Disease
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
This is a phase II trial of reduced intensity conditioning with Bu/Flu/ATG in pediatric patients with hematologic malignancies at high risk for transplant related mortality with standard transplantation.
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia
- Trial name
- NCT00795132
- Testing
- Busulfan, Anti-Thymocyte Globulin, Fludarabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Utah
Waldenstrom's Macroglobulinemia
Simvastatin in Waldenstrom's Macroglobulinemia
This research study seeks to find new ways to treat people with Waldenstrom's Macroglobulinemia (WM). The study is for participants with slow growing WM who otherwise might not need therapy for at least 3-6 months.
- Trial name
- NCT00575965
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Phase IIa study to estimate the efficacy of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as CART-19 or CTL019…
- Trial name
- NCT02030834
- Testing
- CART-19
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
The purpose of this study is to assess the safety and tolerability of Elotuzumab when given in combination with Lenalidomide and low-dose Dexamethasone in subjects with relapsed or refractory multiple myeloma (MM) in Japan.
- Trial name
- NCT01241292
- Testing
- BMS-901608 (Elotuzumab) 10 mg, BMS-901608 (Elotuzumab) 20 mg
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
The combination lenalidomide plus low-dose dexamethasone (Rd) is an active treatment for Multiple Myeloma (MM) patients, both at diagnosis and at relapse.
- Trial name
- PO-3887 (NCT03440411)
- Testing
- Pomalidomide, Cyclophosphamide, Dexamethasone
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
The primary purpose of this clinical study is to determine the recommended clinical doses of vorinostat (MK-0683) and bortezomib administered in combination to participants with relapsed and/or refractory multiple myeloma (MM).
- Trial name
- NCT00858234
- Testing
- Vorinostat, Bortezomib
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Cutaneous Lymphoma, Cutaneous T-cell Lymphoma
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
The purpose of this study is to determine if vorinostat combined with low-dose total skin electron beam therapy (TSEBT) offers superior clinical benefit (efficacy \& safety) over low-dose TSEBT alone in participants with mycosis…
- Trial name
- NCT01187446
- Testing
- Total skin electron beam therapy (TSEBT), Vorinostat
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Lymphoma, B-Cell, Follicular Lymphoma
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
This is an open-label (doctors and patients know which drug will be given), single center, phase 1/2 clinical trial. The primary objective is to determine whether VR-CHOP provides benefit to patients with previously untreated…
- Trial name
- NCT00634179
- Testing
- Bortezomib, Rituximab, Doxorubicin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)
- Trial name
- NCT01724346
- Testing
- Ibrutinib, Next-line ibrutinib
- Where
- 88 sites in United States, Australia and 14 more
- Volunteers
- 269 people
- Sponsor
- Pharmacyclics LLC.
B-Cell Non-Hodgkin Lymphoma
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
This phase II trial studies how well tailored prednisone reduction works in preventing hyperglycemia in participants with B-cell non-Hodgkin lymphoma receiving combination chemotherapy treatment.
- Trial name
- NCT03505762
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
The purpose of this study is to determine the percentage of people who can attain remission and the length of time such responses to therapy are sustained, as well as the side effects that might result from rituximab and…
- Trial name
- NCT00142116
- Testing
- Thalidomide, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Steven P. Treon, MD, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.